Orion-CuraTeQ and Theramax-Enzene Biosciences partnerships

Home/Pharma News | Posted 18/02/2022 post-comment0 Post your comment

In January 2022, Finnish company Orion Corporation and CuraTeQ Biologics, subsidiary of India’s Aurobindo Pharma, announced their European expansion to the Baltic countries. This follows the December 2021 announcement that the UK’s Theramex entered into an agreement with India’s Enzene Biosciences to develop, register and commercialize a biosimilar of Roche’s RoActemra® (tocilizumab).

16704526_l

Orion-CuraTeQ expansion
Under the terms of the agreement, Orion will now have the right to sell and market CuraTeQ’s biosimilars in the Nordic countries, the Baltic countries, Austria, Hungary and Slovenia. At the time of writing, all the products under the agreement were in development or regulatory phases with launches estimated between 2023–2026.

Orion has similar agreements with other companies, such as their agreement with Amgen to distribute Amgevita in Finland [1].

CuraTeQ has a growing portfolio of biosimilars approved and in development. In late 2021, the company submitted an application to the European Medicines Agency for its biosimilar to Amgen’s Neulasta (pegfilgrastim) [2].

Theramex-Enzene Biosciences agreement
Theramex is a specialty pharmaceutical company dedicated to women’s health. Together with Enzene Biosciences, the company plans to commercialize the tocilizumab biosimilar from 2026 in Europe, Switzerland, the UK and Australia. Tocilizumab is used in combination with methotrexate and is indicated for the treatment of rheumatoid arthritis.

This agreement is a follow-up to the June 2021 a license and supply agreement between Theramex and Enzene Biosciences to market a Prolia (denosumab) biosimilar in Europe and Australia [3]. Enzene Biosciences has also partnered with Alkem Laboratories in India to launch a teriparatide ‘similar biologic’ [4].

Related articles
Aurobindo and Huons refocus their biologicals/biosimilars portfolios

Biosimilars of tocilizumab

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Biosimilares aprobados en Colombia

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Biosimilares aprobados en Colombia

iExplore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

References
1. GaBI Online - Generics and Biosimilars Initiative. Amgen collaborates with Orion to market Amgevita in Finland [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 18]. Available from: www.gabionline.net/pharma-news/Amgen-collaborates-with-Orion-to-market-Amgevita-in-Finland
2. GaBI Online - Generics and Biosimilars Initiative. CuraTeQ submits application to EMA for pegfilgrastim biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 18]. Available from: www.gabionline.net/biosimilars/news/curateq-submits-application-to-ema-for-pegfilgrastim-biosimilar
3. GaBI Online - Generics and Biosimilars Initiative. Theramex to market Prolia biosimilar in Europe and Australia [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 18]. Available from: www.gabionline.net/pharma-news/theramex-to-market-prolia-biosimilar-in-europe-and-australia
4. GaBI Online - Generics and Biosimilars Initiative. Australian and Indian approval for teriparatide products [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 18]. Available from: www.gabionline.net/biosimilars/news/Australian-and-Indian-approval-for-teriparatide-products

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
GaBI news digest for 14 October 2022
56 AA011042
Home/Pharma News Posted 14/10/2022
Novartis is set to spin-off Sandoz
Guidance V13F21
Home/Pharma News Posted 16/09/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010